Skip to main content

Table 1 Baseline demographic and clinical characteristics according to tertiles of SD of HbA1c and SD of FPG

From: Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus

 

Classified by tertile of SD of HbA1c

Classified by tertile of SD of FPG

First tertile group (n = 79)

Second tertile group (n = 80)

Third tertile group (n = 80)

P value

First tertile group (n = 79)

Second tertile group (n = 80)

Third tertile group (n = 80)

P value

Age (year)a

65.97 ± 5.52

64.36 ± 7.30

64.88 ± 5.74

0.253

65.27 ± 6.09

64.71 ± 6.08

65.23 ± 6.62

0.825

Sex, female (%)b

36 (45.57)

42 (52.50)

47 (58.75)

0.252

41 (50.00)

47 (59.49)

37 (47.44)

0.279

BMI (kg/m2)a

24.43 ± 2.94

23.58 ± 2.71

23.79 ± 2.81

0.147

23.89 ± 2.89

23.44 ± 2.75

24.46 ± 2.79

0.074

SBP (mm Hg)a

152.92 ± 11.85

153.01 ± 8.71

156.02 ± 8.99

0.083

152.35 ± 8.16

153.56 ± 9.70

156.03 ± 11.61

0.061

DBP (mm Hg)a

83.68 ± 9.54

80.81 ± 7.73

82.92 ± 7.08

0.073

83.06 ± 8.34

82.38 ± 7.35

81.96 ± 8.99

0.701

Heart rate (bpm)a

74.82 ± 9.65

76.01 ± 9.09

74.34 ± 8.89

0.498

74.65 ± 10.78

75.30 ± 7.30

75.23 ± 9.31

0.888

Duration of diabetes (years)c

3.00 (2.85, 3.25)

3.00 (2.85, 3.27)

3.00 (2.82, 3.33)

0.905

3.00 (2.90, 3.35)

3.00 (2.69, 3.13)

3.00 (2.93, 3.19)

0.342

Current smoking, n (%)b

8 (10.13)

9 (11.25)

7 (8.75)

0.871

8 (9.76)

8 (10.13)

8 (10.26)

0.994

Current drinking, n (%)b

5 (6.33)

6 (7.50)

5 (6.25)

0.940

7 (8.54)

3 (3.80)

6 (7.69)

0.442

Hypertension history, n (%)b

62 (78.48)

60 (75.00)

65 (81.25)

0.631

64 (78.05)

61 (77.22)

62 (79.49)

0.941

FPG (mmol/L)a

9.80 ± 1.50

9.80 ± 1.57

10.14 ± 1.54

0.269

9.97 ± 1.43

9.99 ± 1.46

9.78 ± 1.72

0.625

HbA1c (%)a

10.01 ± 2.00

10.17 ± 1.53

10.62 ± 1.34

0.061

10.21 ± 1.44

10.19 ± 1.76

10.40 ± 1.77

0.684

TCHO (mmol/L)a

5.10 ± 0.99

5.36 ± 0.96

5.39 ± 1.00

0.127

5.41 ± 0.91

5.27 ± 0.96

5.18 ± 1.08

0.332

TG (mmol/L)a

1.89 ± 1.11

1.61 ± 0.84

1.73 ± 1.01

0.200

1.65 ± 0.88

1.65 ± 0.88

1.92 ± 1.18

0.139

HDL-c (mmol/L)a

1.37 ± 0.45

1.41 ± 0.48

1.38 ± 0.50

0.893

1.38 ± 0.50

1.36 ± 0.41

1.42 ± 0.52

0.768

LDL-c (mmol/L)a

3.35 ± 1.15

3.63 ± 1.11

3.67 ± 1.21

0.167

3.70 ± 1.08

3.58 ± 1.03

3.38 ± 1.33

0.215

Hypoglycemic agents, n (%)b

        

 Metformin

73 (92.41)

72 (90.00)

75 (93.75)

0.675

74 (90.24)

74 (93.67)

72 (92.31)

0.720

 Gliclazide

39 (49.37)

34 (42.50)

35 (43.75)

0.653

37 (45.12)

36 (45.57)

35 (44.87)

0.996

 Other sulfonylurea

24 (30.38)

21 (26.25)

22 (27.50)

0.839

22 (26.83)

18 (22.78)

27 (34.62)

0.245

 Thiazolidinedione

7 (8.86)

5 (6.25)

8 (10.00)

0.681

11 (13.41)

4 (5.06)

5 (6.41)

0.120

 Acarbose

15 (18.99)

15 (18.75)

11 (13.75)

0.613

19 (23.17)

12 (15.19)

10 (12.82)

0.189

 Glinide

4 (5.06)

4 (5.00)

3 (3.75)

0.905

5 (6.10)

4 (5.06)

2 (2.56)

0.551

 Insulin

9 (11.39)

7 (8.75)

7 (8.75)

0.809

8 (9.76)

8 (10.13)

7 (8.97)

0.969

Other drugs, n (%)b

        

 Antihypertension drug

57 (72.15)

56 (70.00)

63 (79.63)

0.425

58 (70.73)

58 (73.42)

60 (76.92)

0.673

 Aspirin

56 (70.89)

49 (61.25)

43 (53.75)

0.084

51 (62.20)

47 (59.49)

50 (64.10)

0.836

 Statins

11 (13.92)

13 (16.25)

11 (13.75)

0.883

12 (14.63)

12 (15.19)

11 (14.10)

0.982

  1. Results are means ± SDs or medians (25th, 75th percentiles) for continuous variables and numbers (percentages) for categorical variables
  2. SD standard deviation, HbA1c hemoglobin A1c, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, TCHO total cholesterol, TG triglycerides, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol
  3. acompared using ANOVA with Bonferroni procedure
  4. bcompared using Chi-square test
  5. ccompared using Kruskal-Wallis test